These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10609497)

  • 1. Lack of the predominant BRCA1 and BRCA2 mutations in Jewish ovarian carcinoma patients who previously underwent ovulation induction.
    Menczer J; Lerner-Geva L; Sade-Bruchim RB; Friedman E
    Eur J Gynaecol Oncol; 1999; 20(5-6):371-2. PubMed ID: 10609497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
    Moslehi R; Chu W; Karlan B; Fishman D; Risch H; Fields A; Smotkin D; Ben-David Y; Rosenblatt J; Russo D; Schwartz P; Tung N; Warner E; Rosen B; Friedman J; Brunet JS; Narod SA
    Am J Hum Genet; 2000 Apr; 66(4):1259-72. PubMed ID: 10739756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.
    Shiri-Sverdlov R; Oefner P; Green L; Baruch RG; Wagner T; Kruglikova A; Haitchick S; Hofstra RM; Papa MZ; Mulder I; Rizel S; Bar Sade RB; Dagan E; Abdeen Z; Goldman B; Friedman E
    Hum Mutat; 2000 Dec; 16(6):491-501. PubMed ID: 11102978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer.
    Lu KH; Cramer DW; Muto MG; Li EY; Niloff J; Mok SC
    Obstet Gynecol; 1999 Jan; 93(1):34-7. PubMed ID: 9916952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients.
    Tobias DH; Eng C; McCurdy LD; Kalir T; Mandelli J; Dottino PR; Cohen CJ
    Gynecol Oncol; 2000 Aug; 78(2):148-51. PubMed ID: 10926794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
    Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D
    Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1/BRCA2 mutations and breast cancer in Ashkenazi Jewish women.
    Gilbert F; Dabney MK; Diemer K; Ludwig S; Rosenthal G; Osborne MP
    Ann N Y Acad Sci; 1997 Dec; 833():198-203. PubMed ID: 9616755
    [No Abstract]   [Full Text] [Related]  

  • 8. High frequency of BRCA1 and BRCA2 mutations in Ashkenazi Jewish ovarian cancer patients.
    Wallach RC
    Gynecol Oncol; 1998 Jul; 70(1):152. PubMed ID: 9698609
    [No Abstract]   [Full Text] [Related]  

  • 9. BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and ovarian cancer.
    Schubert EL; Mefford HC; Dann JL; Argonza RH; Hull J; King MC
    Genet Test; 1997; 1(1):41-6. PubMed ID: 10464624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.
    Hartge P; Struewing JP; Wacholder S; Brody LC; Tucker MA
    Am J Hum Genet; 1999 Apr; 64(4):963-70. PubMed ID: 10090881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers.
    Perri T; Lifshitz D; Sadetzki S; Oberman B; Meirow D; Ben-Baruch G; Friedman E; Korach J
    Fertil Steril; 2015 May; 103(5):1305-12. PubMed ID: 25792249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with double primary tumors in the breast and ovary- clinical characteristics and BRCA1-2 mutations status.
    Fishman A; Dekel E; Chetrit A; Lerner-Geva L; Bar-Am A; Beck D; Beller U; Ben-Baruch G; Piura B; Friedman E; Struewing JP; Modan B
    Gynecol Oncol; 2000 Oct; 79(1):74-8. PubMed ID: 11006035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
    Roa BB; Boyd AA; Volcik K; Richards CS
    Nat Genet; 1996 Oct; 14(2):185-7. PubMed ID: 8841191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
    Oddoux C; Struewing JP; Clayton CM; Neuhausen S; Brody LC; Kaback M; Haas B; Norton L; Borgen P; Jhanwar S; Goldgar D; Ostrer H; Offit K
    Nat Genet; 1996 Oct; 14(2):188-90. PubMed ID: 8841192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 and WAF1 polymorphisms in Jewish-Israeli women with epithelial ovarian cancer and its association with BRCA mutations.
    Yair D; Ben Baruch G; Chetrit A; Friedman T; Hirsh Yechezkel G; Gotlieb WH; Fishman A; Beller U; Bar-Am A; Friedman E
    BJOG; 2000 Jul; 107(7):849-54. PubMed ID: 10901555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the probability that Ashkenazi Jewish women carry a founder mutation in BRCA1 or BRCA2.
    Hopper JL; Jenkins MA
    Am J Hum Genet; 1999 Dec; 65(6):1771-6. PubMed ID: 10577931
    [No Abstract]   [Full Text] [Related]  

  • 17. The founder mutations in the BRCA1, BRCA2, and ATM genes in Moroccan Jewish women with breast cancer.
    Kreiss Y; Barak F; Baruch RG; Levy-Lahad E; Pras E; Friedman E
    Genet Test; 2000; 4(4):403-7. PubMed ID: 11216667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer.
    Robson M; Dabney MK; Rosenthal G; Ludwig S; Seltzer MH; Gilewski T; Haas B; Osborne M; Norton L; Gilbert F; Offit K
    Genet Test; 1997; 1(1):47-51. PubMed ID: 10464625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.
    Boyd J; Sonoda Y; Federici MG; Bogomolniy F; Rhei E; Maresco DL; Saigo PE; Almadrones LA; Barakat RR; Brown CL; Chi DS; Curtin JP; Poynor EA; Hoskins WJ
    JAMA; 2000 May; 283(17):2260-5. PubMed ID: 10807385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.
    Modan B; Hartge P; Hirsh-Yechezkel G; Chetrit A; Lubin F; Beller U; Ben-Baruch G; Fishman A; Menczer J; Struewing JP; Tucker MA; Wacholder S;
    N Engl J Med; 2001 Jul; 345(4):235-40. PubMed ID: 11474660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.